Neurotech International Ltd has released a press release.
PANDAS/PANS Patients Show Continued Clinical Improvement
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Earlier from Neurotech International
- Neurotech Receives Additional HREC Approval in Autism
- NTI Receives HREC Approval for Cerebral Palsy Trial
- Phase II/III Autism Clinical Trial Completes Recruitment
- HREC Approval to Extend Phase II/III ASD Trial to Adults
- Neurotech Receives $3.17 Million R&D Tax Incentive Refund
Later from Neurotech International
- Rett Syndrome Patients to Receive NTI164 for 52 Weeks
- Last Patient Completes Treatment in NTIASD2 Clinical Trial
- Phase II/III ASD Trial Successfully Meets Primary Endpoint
- Positive Top-Line Rett Syndrome Clinical Trial Results
- Neurotech Completes $10 Million Capital Raise
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International